Stewart Lyman of Lyman BioPharma Consulting posted a great article in today's Xconomy summarizing some key points and links to more information about the rules governing the Therapeutic Discovery Project Credit which have now been released by the US Treasury Department. Today, a detailed fact sheet was released about the tax credit program and it seems almost perfectly designed for most cell therapy companies.
Lyman points out a few important details about the application schedule including:
1. The Formal IRS applications (Form 8942) will not be available until June 21st or thereabouts.
2. The application period opens on June 21 and ends on July 21. The postmark on the application is deemed to be the date of delivery. Preliminary review of the applications is to be completed by Sept. 30; this is to ensure that applicants are eligible taxpayers and that their applications are complete. Applicants will receive determinations as to whether or not they qualify for credits and/or grants, and how much they will receive, by Oct. 29.
By way of a little more background, the following is excerpted from a March Forbes.com article by Dean Zerbe:
What does the credit cover?
The credit/grant covers research in tax years beginning in 2009 and 2010. The taxpayer is provided a 50% credit/grant for qualified investments in "qualifying therapeutic discovery projects." What expenses count as qualified investments? The aggregate amount of costs paid or incurred in the taxable year for expenses necessary for and directly related to the conduct of a qualifying discovery project. What doesn't count? The pay of employees covered by 162(m)(3) of the tax code--think CEOs--doesn't count. Other excluded items: interest expenses; facility maintenance expenses (e.g. mortgage or rent payments, insurance, utility and maintenance and costs of employment of maintenance personnel); and certain indirect costs (basically general and administrative costs) as defined in the Treasury Regulations at 1.263A-1(e)(4).
What is a qualifying therapeutic discovery project?
According to the legislation, it's a project designed to do one of three things:
--Treat or prevent diseases or conditions by conducting pre-clinical activities, clinical trials and clinical studies, or carrying out research protocols for the purpose of securing federal government approval by the FDA.
--Diagnose diseases or conditions or to determine molecular factors related to diseases or conditions by developing molecular diagnostics to guide therapeutic decisions.
--Develop a product, process or technology to further the delivery or administration of therapeutics.
Finally, to qualify, a venture may not have more than 250 employees in all businesses of the taxpayer--meaning a small biotech project at a big company wouldn't qualify.
Which biotech companies might benefit?
Those that are investing significant resources in pre-clinical or clinical studies, which may take years to come to fruition to ultimately satisfy FDA requirements, could now recoup a significant portion of their expenses. Additionally, biotech start-ups focusing on the development of diagnostic assays or applications to advance therapeutics and treatments can also benefit. Finally, companies currently engaged in basic or applied research which may ultimately contribute to curing caner within the next 30 years may also be excellent candidates. Along these lines, companies studying signal transduction pathways, gene therapy and stem cell research seem like prime candidates.
The Cell Therapy Group will be collecting more information about the tax credit and service providers who might be recommended to assist in the application if needed. Contact CTG for more details or watch here for more information.
- Stem cells for a Webby! [Last Updated On: August 18th, 2024] [Originally Added On: April 28th, 2010]
- Latest Cell Therapy Approval by FDA. Dendreon's Provenge. [Last Updated On: August 18th, 2024] [Originally Added On: April 30th, 2010]
- Latest Cell Therapy Approval by FDA. Dendreon's Provenge. [Last Updated On: August 18th, 2024] [Originally Added On: April 30th, 2010]
- Google to Invest in Regenerative Medicine [Last Updated On: August 18th, 2024] [Originally Added On: May 5th, 2010]
- The changing face of PR and why it matters to regenmed [Last Updated On: August 18th, 2024] [Originally Added On: June 12th, 2010]
- FDA files injunction again Regenerative Sciences citing Regenexx violates regulations [Last Updated On: August 18th, 2024] [Originally Added On: August 12th, 2010]
- Careers in cell therapy & regenerative medicine [Last Updated On: August 18th, 2024] [Originally Added On: October 11th, 2010]
- Careers in cell therapy & regenerative medicine [Last Updated On: August 18th, 2024] [Originally Added On: October 11th, 2010]
- The LinkedIn Cell Therapy Industry Group - 1,000 members strong [Last Updated On: August 18th, 2024] [Originally Added On: February 14th, 2011]
- Cell Therapies: Commercializing a New Class of Biopharmaceuticals [Last Updated On: August 18th, 2024] [Originally Added On: February 14th, 2011]
- In vivo cell trafficking just took a leap forward [Last Updated On: August 18th, 2024] [Originally Added On: July 3rd, 2011]
- Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations [Last Updated On: August 18th, 2024] [Originally Added On: July 10th, 2011]
- Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations [Last Updated On: August 18th, 2024] [Originally Added On: July 10th, 2011]
- Clinical trial costs [Last Updated On: August 18th, 2024] [Originally Added On: July 31st, 2011]
- Good Data? $100. Good Product Development? $100. Good Commercialization Strategy? Priceless. [Last Updated On: August 18th, 2024] [Originally Added On: August 14th, 2011]
- Potential far-reaching implications of the ongoing fight over point-of-care autologous cell therapy [Last Updated On: August 18th, 2024] [Originally Added On: September 18th, 2011]
- Commercial-stage Cell Therapy Companies and Products [Last Updated On: August 18th, 2024] [Originally Added On: September 18th, 2011]
- Cell Therapy & Regenerative Medicine Domains Available [Last Updated On: August 18th, 2024] [Originally Added On: September 25th, 2011]
- Cell Therapy & Regenerative Medicine Domains Available [Last Updated On: August 18th, 2024] [Originally Added On: September 25th, 2011]
- Commercializing Cell-based Regenerative Medicines [Last Updated On: August 18th, 2024] [Originally Added On: November 13th, 2011]
- Sabrina Cohen Foundation Thanks Stem Cell Researchers [Last Updated On: August 18th, 2024] [Originally Added On: November 27th, 2011]
- Active phase III or II/III cell therapy trials [Last Updated On: August 18th, 2024] [Originally Added On: December 11th, 2011]
- Recently approved cell therapy products [Last Updated On: August 18th, 2024] [Originally Added On: December 18th, 2011]
- Inactive and recently failed or terminated phase III or II/III cell therapy trials [Last Updated On: August 18th, 2024] [Originally Added On: December 18th, 2011]
- 2011 EMA Committee for Advanced Therapies (CAT) classification record. What can be learned? [Last Updated On: August 18th, 2024] [Originally Added On: January 1st, 2012]
- Predicting the Success of the Late-Stage Cell-Based Cancer Immunotherapy Pipeline? [Last Updated On: August 18th, 2024] [Originally Added On: March 11th, 2012]
- Another > $100M month for companies in the cell therapy space [Last Updated On: August 18th, 2024] [Originally Added On: May 6th, 2012]
- Another > $100M month for companies in the cell therapy space [Last Updated On: August 18th, 2024] [Originally Added On: May 6th, 2012]
- Cell-based Cancer Immunotherapies. Some metrics.. [Last Updated On: August 18th, 2024] [Originally Added On: May 20th, 2012]
- Industry-sponsored cardiovascular cell therapies. Some metrics. [Last Updated On: August 18th, 2024] [Originally Added On: May 27th, 2012]
- Bioreactor Design and Bioprocess Controls for Industrialized Cell Processing [Last Updated On: August 18th, 2024] [Originally Added On: June 17th, 2012]
- FDA 1. RSI 0. Regenerative Sciences (Regenexx) vs FDA (2012) [Last Updated On: August 18th, 2024] [Originally Added On: July 29th, 2012]
- Is the cell therapy sector outperforming the major indices? [Last Updated On: August 18th, 2024] [Originally Added On: August 12th, 2012]
- Are some cell counts too good to be true? Why some companies' product data may mislead. [Last Updated On: August 18th, 2024] [Originally Added On: September 2nd, 2012]
- Are some cell counts too good to be true? Why some companies' product data may mislead. [Last Updated On: August 18th, 2024] [Originally Added On: September 2nd, 2012]
- Two lessons I learned this week. [Last Updated On: August 18th, 2024] [Originally Added On: September 16th, 2012]
- The cost of clinical trial data bias/loss, FDA's new job and the need for bold leadership. [Last Updated On: August 18th, 2024] [Originally Added On: September 30th, 2012]
- Anticipated short-term cell therapy industry clinical milestones [Last Updated On: August 18th, 2024] [Originally Added On: September 30th, 2012]
- The cost of clinical trial data bias/loss, FDA's new job and the need for bold leadership. [Last Updated On: August 18th, 2024] [Originally Added On: September 30th, 2012]
- Cell therapy portfolio outperforms major indices year-to-date [Last Updated On: August 18th, 2024] [Originally Added On: October 14th, 2012]
- CIRM addresses some tough questions. Is it all just glass towers and basic research? [Last Updated On: August 18th, 2024] [Originally Added On: October 21st, 2012]
- GEN's "Cellular Therapy Wave Finally Cresting". An overview and data set. [Last Updated On: August 18th, 2024] [Originally Added On: November 4th, 2012]
- GEN's "Cellular Therapy Wave Finally Cresting". An overview and data set. [Last Updated On: August 18th, 2024] [Originally Added On: November 4th, 2012]
- Cell Therapy Industry Group Welcomes its 4,000th member [Last Updated On: August 18th, 2024] [Originally Added On: November 11th, 2012]
- Six steps to fighting non-compliant cell therapy treatments. --- The stuff of grey shades, spades, ivory towers and (ahem) balls. [Last Updated On: August 18th, 2024] [Originally Added On: December 2nd, 2012]
- A proposed 6-step platform for the cell therapy industry to consider in combating non-compliant cell therapy treatments [Last Updated On: August 18th, 2024] [Originally Added On: December 16th, 2012]
- The ROI on pant-wearing and other social media tips [Last Updated On: August 18th, 2024] [Originally Added On: December 16th, 2012]
- The Accuracy of Adipose Stem Cell Doses [Last Updated On: August 18th, 2024] [Originally Added On: December 23rd, 2012]
- Cell Therapy Blog welcomes 2013 [Last Updated On: August 18th, 2024] [Originally Added On: January 6th, 2013]
- 2013 Annual Regenerative Medicine Industry Report [Last Updated On: August 18th, 2024] [Originally Added On: April 21st, 2013]
- Commercialization of Regenerative Medicine: Learning from Spin-Outs [Last Updated On: August 18th, 2024] [Originally Added On: April 28th, 2013]